Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5603
Name T-cell acute lymphoblastic leukemia
Definition An acute lymphoblastic leukemia that is characterized by too many T-cell lymphoblasts found in the bone marrow and blood.
Source DiseaseOntology.org
Alt Ids DOID:715 DOID:5599
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK3 M511I Tofacitinib T-cell acute lymphoblastic leukemia sensitive detail...
JAK3 M511I Ritlecitinib T-cell acute lymphoblastic leukemia sensitive detail...
JAK3 M511I Selumetinib T-cell acute lymphoblastic leukemia sensitive detail...
JAK3 M511I Dexamethasone + Tofacitinib T-cell acute lymphoblastic leukemia sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02112916 Phase III Cyclophosphamide Vincristine Sulfate Ifosfamide Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Leucovorin Daunorubicin Dexamethasone Bortezomib Etoposide Doxorubicin Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Active, not recruiting USA | NZL | CAN | AUS 0
NCT02518113 Phase Ib/II Dexamethasone LY3039478 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Completed USA | ITA | FRA | DEU 1
NCT02535806 Phase II Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults Terminated USA 0
NCT02881086 Phase III Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Active, not recruiting DEU 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03328104 Phase I Cyclophosphamide + Etoposide + Everolimus + Nelarabine Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT) Completed USA 0
NCT03590171 Phase II Bortezomib International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Recruiting NLD | ITA | GBR | FRA | BEL | AUT | AUS 8
NCT03829540 Phase I CD4CAR CD4CAR for CD4+ Leukemia and Lymphoma Recruiting USA 0
NCT04128501 Phase II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Recruiting USA 0
NCT04307576 Phase III Imatinib Blinatumomab Inotuzumab ozogamicin A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting NLD | GBR | FRA | DEU | BEL 9
NCT04315324 Phase II OBI-3424 Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) Recruiting USA 0
NCT04502446 Phase I CTX130 A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies Active, not recruiting USA | CAN | AUS 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Active, not recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04972942 Phase I Daratumumab Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma (ALLO-T-DART) Recruiting USA 0
NCT04984356 Phase Ib/II WU-CART-007 A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL Active, not recruiting USA | NLD | FRA | AUS 0
NCT05032183 Phase Ib/II Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate Tagraxofusp-erzs Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting USA 0
NCT05038644 Phase I XmAb18968 XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia Recruiting USA 0
NCT05268003 Phase II Ponatinib Venetoclax A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia Recruiting USA 0
NCT05289687 Phase II Daratumumab and hyaluronidase-fihj Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL Recruiting USA 0
NCT05292664 Phase I Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies Recruiting USA 0
NCT05464836 Phase II CB-103 + Venetoclax Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL Recruiting USA 0
NCT05581030 Phase I Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Recruiting USA 0
NCT05679895 Phase I CD1a CAR T cells Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL) Recruiting ESP 0
NCT05885464 Phase Ib/II BEAM-201 A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) Recruiting USA 0
NCT06207123 Phase Ib/II Dexamethasone + Methotrexate + Vincristine Sulfate LP-118 + Ponatinib A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Not yet recruiting USA 0
NCT06326463 Phase I CD70-CAR-T cells Cyclophosphamide + Fludarabine Mesna CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Not yet recruiting USA 0